
Keywords: BC; breast cancer; LAR; Luminal Androgen receptor; BL1; Basal Like 1; BL2; Basal Like 2; MSL; Mesenchymal Stem-Like; M; mesenchymal; IM; immunomodulatory; UNS; unstable; HR; homologous recombination; pCR; pathologic complete response; ORR; Objective Respo